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Histone lysine demethylase KDM4/JMJD2s are over-
expressed in many human tumors including prostate
cancer (PCa). KDM4s are co-activators of androgen
receptor (AR) and are thus potential therapeutic tar-
gets. Yet to date few KDM4 inhibitors that have
anti-prostate tumor activity in vivo have been devel-
oped. Here, we report the anti-tumor growth effect
and molecular mechanisms of three novel KDM4 in-
hibitors (A1, I9, and B3). These inhibitors repressed
the transcription of both AR and BMYB-regulated
genes. Compound B3 is highly selective for a variety
of cancer cell lines including PC3 cells that lack AR.
B3 inhibited the in vivo growth of tumors derived
from PC3 cells and ex vivo human PCa explants.
We identified a novel mechanism by which KDM4B
activates the transcription of Polo-like kinase 1
(PLK1). B3 blocked the binding of KDM4B to the
PLK1 promoter. Our studies suggest a potential
mechanism-based therapeutic strategy for PCa and
tumors with elevated KDM4B/PLK1 expression.
INTRODUCTION
Histone methylation is an emerging epigenetic mechanism in-
volved in tumorigenesis (Berry and Janknecht, 2013). KDM4/
JMJD2s are histone demethylases that act on di- and tri-methyl-
ated histone H3 lysine 9 (H3K9me2/me3). Some KDM4s can
also demethylate methylated H3K36 in vitro (Whetstine et al.,
2006). H3K9me3 is normally associated with constitutive and
facultative heterochromatins that are condensed and trans-
criptionally silent. Facultative heterochromatin can decondense
upon loss of H3K9me3 and become transcriptionally permissive
in response to specific developmental and environmental cues
such as growth factor and/or stress signaling (Zhang and Liu,Chemistry & Biology 22, 1185–1192015). Thus, overexpression of KDM4 is usually associated
with downregulation of H3K9me3 and gene activation. The hu-
man KDM4 family consists of four members, KDM4A, 4B, 4C,
and 4D, and two pseudo-genes, KDM4E and KDM4F (Katoh
and Katoh, 2004). KDM4A, 4B, and 4C contain a catalytic histone
demethylase domain (jmj domain), and double PHD and Tudor
domains, whereas KDM4D contains only a catalytic domain
and lacks PHD and Tudor domains. KDM4s are ferrous iron-
and 2-oxoglutarate-dependent oxygenases whose enzymatic
activities are amenable to inhibition by small molecules (Rose
et al., 2011). KDM4 proteins are overexpressed in a variety of hu-
man disorders including cancer, mental retardation, and cardio-
vascular diseases, and are emerging drug targets for cancers
(Young and Hendzel, 2013). KDM4 proteins are co-activators
of androgen receptor (AR) (Gao and Alumkal, 2010; Metzger
et al., 2005; Shin and Janknecht, 2007; Wissmann et al., 2007;
Coffey et al., 2013). Overexpression of KDM4 proteins in PCa
cells was hypothesized to heighten the sensitivity of AR signaling
in castration-resistant prostate cancer (CRPC) under castrated
levels of androgen (Gao and Alumkal, 2010). Many small-mole-
cule inhibitors of KDM4 have been identified (Rose et al., 2011;
King et al., 2010; Thalhammer et al., 2011; Hamada et al.,
2010; Wang et al., 2013; Chu et al., 2014). However, few com-
pounds have data available on their anti-cancer properties and
mechanisms of action. Major challenges to the development of
KDM4 inhibitors are their specificity and selectivity. Such chal-
lenges underscore the need to better understand themechanism
of action of KDM4 in tumor cells and to test any KDM4 inhibitors
in the context of such knowledge.
A high-throughput screen for inhibitors of KDM4E was per-
formed as part of the lead optimization projects in the NIH for
epigenetic targets (King et al., 2010). One of the inhibitors iden-
tified, 8-hydroxyquinoline (8HQ), has a 10-fold higher selectivity
for the KDM4 family of histone demethylases over other 2-oxo-
glutarate oxygenases such as prolyl hydroxylase domain 2
(PHD2). A series of chemical compounds were generated based
on the 8HQ chemotype (Rai et al., 2010–2012). However, the
anti-tumor activity and specificity of these compounds remain
to be determined. Here, we identified three KDM4 inhibitors6, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1185
(B3, A1, and I9) derived from 8HQ and characterized their
anti-tumor growth activities. Among them, compound B3 is
the most potent; it is highly selective for PC3 cells that are
androgen independent. More importantly, B3 is also an active
agent in an ex vivo human PCa explant model containing het-
erogeneous tumors and an in vivo xenograft tumor model. Using
these compounds, we uncovered a previously unrecognized
mechanism by which KDM4B promotes PCa tumorigenesis.
Uniquely, we show that KDM4B appears to be a potent factor
in prostate tumorigenesis compared with other KDM4 isoforms.
In addition to regulating transcription of AR-dependent genes,
KDM4B also regulates gene transcription in an AR-independent
manner. KDM4B binds the transcription factor BMYB to acti-
vate BMYB-targeted cell-cycle genes including Polo-like kinase
1 (PLK1). We show that these compounds had similar effects
on tumor cell-cycle progression and gene transcription as
KDM4B knockdown, demonstrating a mechanistic action of
novel small-molecule inhibitors of KDM4 in targeting prostate
tumor growth.
RESULTS
Identification and Characterization of Novel KDM4
Inhibitors that Block Prostate Tumor Cell Growth
Based on structure-activity relationship studies, a series of
chemical compounds were derived from 8HQ and were shown
to be active inhibitors of KDM4E and KDM4A (Rai et al., 2010–
2012). We tested the effect of these compounds on the growth
of LNCaP cells (Figure S1A) and selected NCGC00247751
(A1), NCGC00244536 (B3), and NCGC00247743 (I9), which in-
hibited LNCaP cell growth with half-maximal inhibitory con-
centrations (IC50) in the micromolar range (Figure 1A). These
inhibitors suppressed the catalytic activity of KDM4B effec-
tively and among them B3 was the most potent, with an IC50
of 10 nM (Figure 1B). These compounds also inhibited the
enzymatic activity of other KDM4 isoforms although, interest-
ingly, the potency and efficacy of B3 and A1 for KDM4A, 4C,
and 4D are lower compared with that of I9, suggesting a po-
tential selectivity of the inhibitors for different isoforms of
KDM4. These inhibitors had no or weak activity for KDM5A/
JARID1A. KDM5A, like KDM4B, is a trimethyllysine dioxyge-
nase but demethylates H3K4me3 specifically. The three inhib-
itors had little effect on lysine-specific demethylase 1 (LSD1)
(Figure S1B). LSD1, unlike jmj-C-containing lysine demethy-
lases, is a flavin-dependent monoamine oxidase that deme-
thylates mono- and di-methylated lysines on H3K4 and
H3K9. To verify that the B3 and A1 compounds act by bind-
ing specifically to KDM4s, we used transverse relaxation
enhanced spectroscopy (TROSY)-based 1H-15N heteronuclear
single quantum correlation (HSQC) spectra. These nuclear
magnetic resonance (NMR) spectra are like protein finger-
prints with one cross-peak for each amide group in a protein,
and provide a powerful tool for analysis of protein-ligand inter-
actions (Rizo et al., 2012). Indeed, addition of B3 and A1
caused shifts in specific cross-peaks of the 1H-15N TROSY-
HSQC spectrum of the catalytic domain of KDM4B, and the
shift patterns were markedly different for the two compounds
(Figure 1C), showing that both compounds bind specifically
to the domain and suggesting that the binding modes are1186 Chemistry & Biology 22, 1185–1196, September 17, 2015 ª201distinct. Similar binding of B3 and A1 to KDM4A was also
observed (Figure S1C).
We tested the inhibitory effect of B3 on a panel of prostate
cell lines. B3 displayed high selectivity for the fast-growing
AR-negative PC3 cells (IC50 = 40 nM) and more than 100-
fold selectivity against the immortalized prostate epithelial
cell lines PrEC1 and PrEC4 (Figures 1D and S1D). Also, B3
effectively inhibited AR-positive cell lines, including LNCaP
and VCaP, with IC50s in the submicromolar range (Figure 1D),
and abolished androgen-stimulated LNCaP cell growth (Fig-
ure 1E). In addition, B3 is also potent in inhibiting the growth
of other cancer cell lines, including the breast cancer cell lines
MDA-MB2 and MCF-7, with micromolar IC50s (Figure 1D). We
further tested whether B3 can inhibit tumor growth in vivo by
using a xenograft model with tumors derived from injection
of PC3 cells. PC3 cells were injected to the flanks of SCID
mice. After the tumor volume reached 50 mm3, we began daily
treatment with 20 mg/kg of B3 or vehicle control. Treatment
with B3 resulted in significant inhibition of tumor growth (Fig-
ure 1F), and animals did not exhibit any major toxicity and
appeared normal. Histological data clearly indicated that B3-
treated tumors had a significant amount of cell apoptosis, ne-
crosis, and fibrosis (Figure 1G).
KDM4 Inhibitors Has Inhibitory Effects on Prostate
Tumor Cell-Cycle Progression Similar to Those of
KDM4B Knockdown
We were intrigued by the sensitivity of PC3 cells to compound
B3, since PC3 cells have no AR. We reasoned that KDM4B
may have an AR-independent mechanism or may not target
KDM4 proteins in PC3 cells. We explored these two possibilities
by firstly testing whether KDM4 inhibitor-treated PCa cells and
KDM4 knockdown cells have similar cellular phenotypes, and
then testing whether KDM4 inhibitors and KDM4 knockdown
have common transcriptional targets.
We tested the role of individual KDM4 isoform in prostate cell
growth, as they are all expressed in PCa cells (Figure S2A). We
surveyed the expression levels of KDM4 isoforms in previously
published gene expression datasets that contained normal pros-
tate tissue, primary PCa, and metastatic CRPC (GEO: GDS2545
and GSE32269; Cai et al., 2013; Chandran et al., 2007; Yu et al.,
2004). KDM4B is the major isoform expressed in prostate tis-
sues, and its expression is upregulated in primary PCa and
further upregulated in CRPCs significantly, whereas the expres-
sion of KDM4A, 4C, and 4D remain similar among normal and
cancerous tissues (Figure 2A). We knocked down 4A, 4B, and
4Cwith two specific small interfering RNAs (siRNAs) for each iso-
form to test the effect of different KDM4 isoforms on the growth
of LNCaP and PC3 cell lines (Figures 2B, S2A, and S2B). Knock-
down of KDM4A, 4B, or 4C inhibited the cell growth of both
LNCaP and PC3 cells significantly, and the strongest effects
on growth were caused by the KDM4B siRNAs (Figure 2C). We
next investigated the effect of KDM4A or KDM4B knockdown
on cell-cycle progression using flow cytometry (FACS) analysis.
Since two independent siRNA duplexes resulted in similar effect
on PCa cell growth, we focused on one of the siRNA duplexes in
the following experiments. LNCaP and PC3 cells were trans-
fected with control, KDM4A, or KDM4B siRNA, pulse labeled
with bromodeoxyuridine (BrdU), stained with propidium iodide5 Elsevier Ltd All rights reserved
Figure 1. Novel KDM4 Inhibitors Selectively Inhibit Prostate Tumor Growth
(A) Cell viability response of LNCaP cells to compounds B3, A1, and I9. The chemical structures of B3, A1, and I9 are shown.
(B) Dose-response curves of KDM4B, 4A, 4C, 4D, and KDM5A demethylase activities to various concentrations of B3, A1, and I9.
(C) Expansions of 1H-15N TROSY-HSQC spectra of KDM4B in the presence (red contours) and absence (black contours) of compounds B3 (left) or A1 (right).
(D) IC50 values reflecting the effects of B3 on the viability of various prostate immortalized epithelial and cancer cell lines, as well as cervical and breast cancer cell
lines. Viable cells were quantified by MTT assays. The IC50 values of the compounds were calculated by curve-fitting using GraphPad (n = 6, mean ± SD).
(E) LNCaP cells were cultured in the presence or absence of the androgen agonist R1881 and/or compound B3 as indicated.
(F) PC3 xenograft tumor volume in SCID mice after treatment with vehicle or compound B3. n = 9 (vehicle treated) and 10 (B3 treated), mean ± SD. *p < 0.05,
compared with vehicle-treated tumors.
(G) H&E staining of representative tumors treated with vehicle or B3. Magnification 203.and anti-BrdU antibody, and subjected to FACS analysis (Fig-
ure S2D). The percentage of cells in S phase was significantly
decreased in LNCaP cells transfected with KDM4B siRNA com-
pared with those transfected with control siRNA (Figure 2D, left).
Downregulation of S-phase cells by KDM4B siRNA is not due toChemistry & Biology 22, 1185–119the off-target effect of siRNA, as adding back exogenously ex-
pressed siRNA-resistant KDM4B in KDM4B siRNA-treated cells
rescued the cell-cycle phenotype (Figure S2E).
Downregulation of S-phase cells is evenmore dramatic in fast-
cycling PC3 cells that were transfected with either KDM4B or6, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1187
Figure 2. KDM4 siRNA and Inhibitors Inhibit DNA Replication of PCa Cells
(A) Relative expression levels of KDM4 isoforms in normal and cancerous prostate tissue samples. Error bars are SEM. *p < 0.05, **p < 0.01.
(B) Western blots of LNCaP cells transfected with control (ctl), KDM4A (4A), KDM4B (4B), or KDM4C (4C) specific siRNA and probed with antibodies against
KDM4A, KDM4B, and GAPDH.
(C) Growth curves of LNCaP (left) and PC3 cells (right) transfected with the indicated siRNA duplexes.
(D) FACS analysis of LNCaP cells (left) and PC3 cells (right) transfected with control (ctl), 4A, or 4B specific siRNA. Two different siRNA duplexes were used.
Representative ones are shown here. n = 3, mean ± SD. *p < 0.05 compared with control siRNA-transfected cells.
(E) FACS analysis of LNCaP and PC3 cells treated with vehicle DMSO, I9 (10 mM), A1 (5 mM), or B3 (1 mM). n = 3, mean ± SD. *p < 0.05 compared with DMSO-
treated cells.
(F) Percentage of apoptotic cells treated with vehicle, A1, or B3 as assayed by Annexin V staining.KDM4A siRNA. Knockdown of KDM4B resulted in cell-cycle
arrest at G1/S (Figure 2D). Knockdown of KDM4B also led to
cell-cycle arrest at G2/M in PC3 cells (Figure 2D, right). Taken1188 Chemistry & Biology 22, 1185–1196, September 17, 2015 ª201together, these data suggest that among different KDM4 iso-
forms, KDM4B plays a major role in the growth of LNCaP and
PC3 cells.5 Elsevier Ltd All rights reserved
Figure 3. Inhibition of KDM4B by Either
siRNA or Inhibitors Downregulated the Ex-
pressions of Cell-Cycle Genes Including
PLK1
(A) Heatmap of selected downregulated genes from
LNCaP cells treated with I9, A1, or B3. Cell-cycle
genes that are also downregulated in KDM4B
knockdown cells are highlighted in red.
(B) qRT-PCR analysis of selected differentially ex-
pressed transcripts in compound-treated LNCaP
and PC3 cells. mRNAs are expressed relative to
vehicle (ctl)-treated cells.
(C) qRT-PCR analysis of selected genes down-
regulated in KDM4B siRNA-transfected LNCaP and
PC3 cells. mRNAs were normalized against GAPDH
and expressed relative to that in control siRNA-
transfected cells.
(D) Western blots of indicated proteins in LNCaP
and PC3 cells treated without or with compound B3
(left), control, KDM4A, or KDM4B siRNA (right).siRNA, LNCaP, and PC3 cells were treated with B3, A1, and I9
to test whether KDM4 inhibitors have effects on cell-cycle pro-
gression similar to those of KDM4B (Figure 2E). Indeed, we
observed similar decreases in the number of S-phase cells
when cells were treated with compounds B3 and A1. Cell-cycle
arrest at G2/M by compound A1 in fast-cycling PC3 cells is also
observed (Figure 2E, right). Moreover, we observed increased
cell apoptosis of both LNCaP and PC3 cells after treatment
with inhibitors (Figure 2F). Themore severe effect of the inhibitors
on PCa cells in comparison with KDM4B knockdown alone may
be due to the combined action of the compound on various
KDM4B isoforms. Taken together, our data indicate that either
KDM4B knockdown or KDM4 inhibitors had similar inhibitory ef-
fects on cell-cycle progression.
Inhibition of KDM4B Either by siRNA-Depletion or
Inhibitors Downregulates the Expression of Critical
Cell-Cycle Gene PLK1
We performed microarray gene expression profiling with cells
treated with compound B3, A1, or I9 to investigate whether
KDM4B knockdown and KDM4 inhibitors have common tran-
scriptional targets. We reasoned that the common targets of
these three compounds may represent targets of KDM4B. All
three compounds had similar effects on alteration of gene
expression pattern (Figure S3A). We focused on downregulated
genes, as KDM4B is a transcriptional co-activator. There were
186 common downregulated genes (Figure S3B). Consistent
with their effect on cell-cycle progression, gene ontology anal-
ysis indicated that a majority of the genes were nuclear proteins
involved in the cell cycle (Figure S3C). We noticed that some of
the most downregulated genes including PLK1 are not AR-
targeted genes, and have been shown to be regulated by tran-
scription factor BMYB (Sadasivam et al., 2012) (Figure 3A). WeChemistry & Biology 22, 1185–1196, September 17, 2015compared the 186 genes with published
AR- and BMYB-targeted genes identified
by AR and BMYB chromatin immunopre-
cipitation (ChIP)-sequencing experiments
(Cai et al., 2013; Sadasivam et al., 2012).
We found that 15% and 18% of 186 down-regulated genes are potential targets of the transcription factors
AR andBMYB, respectively (Figure S3D).We focused on cell-cy-
cle regulators PLK1, AURKA, BIRC5, and UBE2C (highlighted in
red in Figure 3A), as they have not been shown previously to be
regulated by KDM4B.We confirmed their downregulation in both
inhibitor-treated and KDM4B siRNA-transfected cells using
qRT-PCR (Figures 3B and 3C). Downregulation of PLK1 in
KDM4A-, 4B siRNA-, or B3-treated cells was further confirmed
by western blot analysis (Figure 3D).
Downregulation of cell-cycle gene PLK1 in KDM4B siRNA-
treated cells suggests that PLK1 may be activated by
KDM4B, and we measured the expression of KDM4B at
different cell-cycle phases in LNCaP cells to test this possibility
(Figure 4A). Unlike KDM4A, which is mainly expressed in the
G1/S and early S phases but little in late S phase and G2/M,
KDM4B is expressed throughout the cell cycle. We next as-
sayed the KDM4 demethylase activities and the expression of
PLK1 and other cell-cycle genes at different time points of the
cell cycle after synchronized cells were released from G1/S.
The activities of KDM4 peaked at 4 and 9 hr after entering the
cell cycle (Figure 4B). Coinciding with the maximal expression
of PLK1 at 9 hr post-G1/S, we observed maximal binding of
KDM4B to the PLK1 promoter around the same time point (Fig-
ure 4C). As expected, upregulation of KDM4B binding at the
PLK1 promoter correlated with downregulation of H3K9me3
occupancy at the binding site. The peak activities of KDM4
also coincided with mRNA peaks of UBE2C and BIRC5 at
4 hr, and PLK1, AURKA, and CDK1 at 9 hr (Figure 4D). Com-
pound B3 effectively suppressed the expression of PLK1,
AURKA, and BIRC5 at the appropriate time point. Taken
together, these correlative data suggest that KDM4B could
regulate transcription of PLK1 and B3 could inhibit PLK1 tran-
scription via KDM4B.ª2015 Elsevier Ltd All rights reserved 1189
Figure 4. Cell-Cycle-Dependent PLK1 Ex-
pression Requires KDM4 Activity
(A) Western blot of indicated proteins from thymi-
dine-released LNCaP cells.
(B) Relative KDM4 demethylase activity at various
time points of double thymidine-released LNCaP
cells. The activities were expressed relative to
asynchronized (asy) cells.
(C) Relative occupancy of H3K9me3, KDM4B, and
BMYB on the PLK1 promoter at various time points
of double thymidine-released LNCaP cells. The
amounts of immunoprecipitated complex were
normalized against DNA input and expressed
relative to that from asynchronized cells.
(D) Relative fold change of mRNA of the indicated
genes from LNCaP cells described in (B) in the
presence or absence of compound B3. mRNAs
were expressed relative to the 0-hr time point.KDM4B Activates PLK1 Transcription via BMYB and Its
Recruitment to PLK1 Promoter Is Blocked by
Compound B3
BMYB is part of the MuvB complex during early S phase and the
MuvB/FoxM1 complex in late S phase that act to promote the
expression of early G1/S phase and G2/M phase cell-cycle
genes, respectively (Sadasivam and DeCaprio, 2013). PLK1 is
a master regulator of mitosis (Yuan et al., 2011) and is expressed
maximally in late S phase (Figure 4A). We examined the genomic
sequence of the human PLK1 promoter to test whether PLK1 is
a direct transcriptional target of KDM4B and to understand
the molecular mechanism underlying KDM4B-activated PLK1
transcription (Bra¨uninger et al., 1995), and found two highly
conserved BMYB binding sites at 490 bp (II) and 1181 bp (I)
50-upstream of the transcriptional start site (Figure 5A, circles).
Reporter assays with PLK1 promoter-driven luciferase (PLK1-
luc) showed that KDM4B could activate PLK1 transcription in a
dose-dependent manner (Figure 5A). Activation of PLK1 tran-
scription by KDM4B requires its demethylase activity, as the de-1190 Chemistry & Biology 22, 1185–1196, September 17, 2015 ª2015 Elsevier Ltd All rightsmethylase-inactive mutant KDM4BH189G
failed to activate PLK1 transcription.
Interestingly, KDM4BH189G acted as a
dominant-negative form in LNCaP cell-
growth assay (Figure S4A). Further re-
porter assays with deletion and point-mu-
tation variants of the PLK1 promoter
indicated that KDM4B activated PLK1
transcription through BMYB binding site
II at 490 bp (Figure 5A). Maximal activa-
tion of PLK1 transcription by BMYB re-
quires endogenous KDM4B, as depletion
of KDM4B by siRNA resulted in a sig-
nificant loss of BMYB-activated PLK1
transcription (Figure 5B). We next tested
whether BMYB can interact with
KDM4B, therefore recruiting it to the
PLK1 promoter. Indeed, we observed
endogenous interaction between BMYB
and KDM4B in a co-immunoprecipitation
assay (Figure 5C). Further co-immuno-precipitation assays suggested that the region between the
N-terminal jmjC domain and C-terminal PHD domain of
KDM4B (residues 430–710) was sufficient tomediate the interac-
tion between KDM4B and BMYB (Figure 5D). We further tested
the effect of B3 on the binding of KDM4B to the promoter of
PLK1 in LNCaP cells. B3 disrupted the loading of KDM4B to
the PLK1 promoter around the BMYB binding site without
affecting BMYB binding (Figure 5E). Downregulation of KDM4B
binding to the PLK1 promoter is not due to a loss of KDM4B
protein, as B3 treatment at the concentration used (1 mM) had
little effect on KDM4B protein level (Figure 3D). Loss of
KDM4B on the PLK1 promoter is associated with upregulation
of H3K9me3 and downregulation of H3K4me3 on the PLK1 pro-
moter (Figure 5E). Upregulation of H3K9me3 is likely due to
decreased binding of KDM4B on the PLK1 promoter, since
H3K9me3 is a substrate of KDM4B, whereas downregulation
of H3K4me3 may be an indirect effect and consequence of tran-
scriptionally less active genes. B3 also significantly diminished
the binding of KDM4B to the promoter/enhancer regions ofreserved
Figure 5. KDM4B Interacts with BMYB and Activates BMYB-Targeted PLK1 Transcription
(A) PLK1-luc reporter activities in cells transfected with full-length (1.5 kb), deletion (1.0, 0.5 kb) or point-mutant (x) of a PLK1-promoter construct and a vector that
expresses KDM4B, KDM4BH189G, or BMYB as indicated.
(B) PLK1-luc activity in control, KDM4A (2A), or KDM4B (2B) knocked down cells that were transfected with various amount of BMYB.
(C) LNCaP cell lysates were immunoprecipitated with control immunoglobulin G (IgG) or anti-KDM4B antibody, respectively. Immunoprecipitates were Western
blotted with antibodies against BMYB and KDM4B.
(D) 293T cells were transfected with Flag-BMYB and HA-KDM4B (lower left) or various deletion mutants of KDM4B (right). Whole cell lysates were immuno-
precipitated with anti-FLAG antibody and immunoprecipitates were western blotted with anti-HA antibody.
(E) ChIP-qPCR assays showing the relative occupancy of H3K9me3, KDM4B, BMYB, H3K36me3, and H3K4me3 at the PLK1 promoter in LNCaP cells treated
with compound B3 (1 mM) or vehicle DMSO. n = 3, mean ± SD. *p < 0.05.several other genes that are important for cell-cycle progression
(Figure S4B).
B3 Is Active in Human Ex Vivo Prostate Tumor Explants
Next, we tested whether B3 has the same effect on human pros-
tate tumor tissue in terms of target gene expression by using an
ex vivo explant model that contains both human tumor tissue
and its surrounding ‘‘native’’ microenvironment (Centenera
et al., 2012). B3 effectively inhibited the expression of AR (Fig-
ure 6A, upper) and other KDM4B-targeted genes in the prostate
tumors (Figure 6B). No global change of H3K9me3was observed
in B3-treated tumors compared with control vehicle-treated tu-
mors (Figure 6A, middle). We noted that B3 had no effect on
the morphology of stromal cells surrounding the tumor (Fig-
ure 6A, arrow), suggesting that the inhibitory effect of B3 is spe-
cific to tumor cells.
DISCUSSION
Epigenetic control via chromatin modification is recognized
as a fundamental mechanism for regulating gene expression
throughout development and in human diseases, yet we have
only just begun to take advantage of it for therapeutic uses.
KDM4 proteins are overexpressed in variety of human patholog-Chemistry & Biology 22, 1185–119ical conditions, which made them desirable targets for interven-
tional therapy. Moreover, KDM4 proteins are ideal targets for
small-molecule inhibitors compared with transcription factors,
as their enzymatic activities are amenable for inhibition. In this
study, we identified and characterized three novel KDM4 inhibi-
tors (A1, I9, and B3). Our data suggest that these compounds
hold potential promise for therapeutic uses. First, these com-
pounds have nanomolar IC50s for inhibiting KDM4Bdemethylase
activity, which is significantly lower than those of previously
identified inhibitors. Furthermore, they have more than 100-
fold selectivity between cancerous and non-cancerous cells,
although whether this selectivity can be translated into clinical
advantage remains to be seen. Importantly, compound B3 has
expected inhibitory effects on cell-cycle genes in solid ex vivo
human prostate tumors that are highly heterogeneous, impli-
cating that the cell-cycle genes identified here may be used as
biomarkers for evaluating the efficacy of compounds in future
cancer therapy. Lastly, while the B3 compound has not yet
been optimized for systemic administration, localized adminis-
tration of B3 near the tumor site blocked tumor growth in an
in vivo xenograft model using human prostate cancer cells.
This should encourage further medicinal chemistry efforts to
explore the full potential of this compound class as a drug in
future pre-clinical application.6, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1191
Figure 6. Compound B3 Inhibits AR and Critical Cell-Cycle Genes in
Ex Vivo Solid Human Prostate Tumors and Growth of PC3 Xenograft
Tumor In Vivo
(A) Immunohistochemical staining of AR (upper) and H3K9me3 (middle), and
H&E staining (lower) in sections of human prostate tumor in ex vivo cultures in
the presence of vehicle DMSO or B3. B3 had no effect on the morphology of
stromal cells surrounding the tumor (arrow). Magnification 403.
(B) Relative fold change of mRNA of genes as indicated from tissues described
in (A). mRNA levels were normalized against GAPDH and expressed relative to
those in cultures in the presence of DMSO. n = 5, mean ± SD.Although KDM4A, 4B, and 4C are shown to be overexpressed
in many human cancers and promote tumorigenesis through
variety of mechanisms (Berry and Janknecht, 2013; Young and
Hendzel, 2013; Van Rechem et al., 2015; Guerra-Calderas
et al., 2015), the mechanism by which KDM4B activates PLK1
transcription via BMYB in the late S phase of PCa cells has not
previously been reported; therefore, we focused on this mecha-
nism in this study. We found that KDM4B is the major isoform in
PCa tumorigenesis compared with KDM4A and 4C. KDM4B is
significantly upregulated in metastatic PCa and has the stron-
gest effect on PCa growth (Figure 2). This may be due to its
unique role in regulating the expression of PLK1 at late S phase,
since KDM4B is expressed throughout the cell cycle including
the late S phase when PLK1 is maximally expressed, whereas
KDM4A is mainly expressed in G1 and early S phase (Figure 4A).
Although it is possible that the effects of KDM4 inhibition on the
cell cycle may be stress responses and there is a possibility that
the core of the cellular effects of the compounds may result from1192 Chemistry & Biology 22, 1185–1196, September 17, 2015 ª201non-KDM4-mediated metalloenzyme inhibition, several lines of
evidence in our study suggest that the inhibitors we identified
here can target KDM4B specifically in late S phase: (1) PCa cells
treated with either KDM4 inhibitors or KDM4 siRNA had similar
cell-cycle defects (Figure 2); (2) both inhibitors and KDM4B
siRNA inhibited the expressions of similar sets of genes that
include critical cell-cycle regulator PLK1 (Figure 3); (3) the peak
level of KDM4 demethylase activity coincides with a maximal
binding of KDM4B to the PLK1 promoter (Figure 5) and is asso-
ciated with the expression of PLK1 (Figure 4); (4) KDM4B inter-
acts with BMYB and activates PLK1 transcription (Figure 5);
and (5) compound B3 blocked the recruitment of KDM4B to
the PLK1 promoter, which is associated with upregulation of
repressive mark H3K9me3.
The AR-independent mechanism of KDM4B in PCa cells im-
plies that KDM4Bmay play an important role in PCa progression
toward castration resistance, although this remains to be tested
in the future. KDM4B may utilize this AR-independent mecha-
nism to promote PCa cell growth when androgen or AR activity
is low, and thus select for castration-resistant phenotype.
8HQ-derived chemical compounds identified here thus may be
useful for CRPC that are lethal at present. Indeed, we show
that compound B3 is effective in inhibiting growth of CRPC cells
such as PC3 and VCaP cells (Figure 1D).
Activation of PLK1 by KDM4B has also other implications in
cancer therapy, as it may provide alternatives over those target-
ing PLK1 or BMYB. Both PLK1 and BMYB are implicated in
human tumorigenesis (Sadasivam et al., 2012; Sadasivam and
DeCaprio, 2013; Van Rechem et al., 2015; Guerra-Calderas
et al., 2015; Song et al., 2012). PLK1 is a critical regulator for
both DNA replication and chromosome segregation in mitosis
(Yuan et al., 2011; Song et al., 2012). Overexpression of PLK1
has been observed in a variety of solid tumors as well as in acute
myeloid leukemia, and has been correlated with poor prognosis
and metastatic potential (Cholewa et al., 2013). BMYB is part of
theMuvB complex during S phase and of theMuvB/FoxM1 com-
plex in late S phase that act to promote expression of early G1/S
and G2/M phase cell-cycle genes, respectively (Sadasivam and
DeCaprio, 2013). BMYB is frequently overexpressed in tumors
and forms part of the proliferation signature that is characteristic
of high-grade tumors with poor prognosis. Upregulation of
BMYB can drive cells out of quiescence and toward proliferation.
Because of these tumorigenic roles of PLK1 and BYMB, they are
attractive molecular targets for cancer therapy. Various PLK1 in-
hibitors have been developed and are being tested in clinical
trials (Craig et al., 2014). BMYB is a component of the breast
cancer gene expression signature in the Oncotype Dx (Genomic
Health) clinical biomarker test. However, PLK1 and BMYB are
double-edged swords as they are both required for normal
cell-cycle progression. Inhibition of PLK1 and BMYB could
have undesirable side effects in organswith high cell proliferation
such as bone marrow. In contrast, no individual KDM4 isoform is
required for normal development, as mice lacking it are viable
(Zhang et al., 2011; Pedersen et al., 2014; Kawazu et al., 2011;
Iwamori et al., 2011), which could provide a strategy of targeting
KDM4B without interfering with its normal function. Indeed, we
noted that B3 inhibited PLK1 expression by suppressing the
recruitment of KDM4B to the PLK1 promoter without affecting
binding of BMYB to the PLK1 promoter (Figure 5). Thus, it will5 Elsevier Ltd All rights reserved
be worth investigating in the future how KDM4B differentially
regulates BMYB-activated gene transcription between normal
and cancer cells.
H3K9me3 is a heterochromatin mark whose level varies
between and within each cell-cycle phase (Black et al., 2012;
Figure 4A). Although it is possible that inhibition of KDM4 may
alter the global H3K9me3 level, we did not observe significant
changes in global H3K9me3 by KDM4B siRNA knockdown. In
synchronized LNCaP cells we observed two peaks of KDM4
activity that occurred at 4 and 9 hr after release from double
thymidine block (Figure 4B) and had no correlation with changes
in global H3K9me3 during the cell cycle (Figure 4A). On the other
hand, changes of KDM4 demethylase activity are tightly corre-
lated with the peaks of mRNA and protein expression of mul-
tiple cell-cycle genes, including PLK1 and UBE2C in S phase
(Figure 4D). These results suggest that KDM4B regulates
H3K9me3 at specific loci rather than the global H3K9me3 level
during S phase. It is worth noting that majority of the genes
downregulated by KDM4B siRNA or KDM4 inhibitors such as
PLK1, AURKA/B, UBE2C, CENPA, and TPX2 are related to
DNA replication and centrosome amplification and maturation.
These genes regulate cell-cycle progression epistatically and/
or in coordination. The effect of inhibition of KDM4 activity on
the expression of cell-cycle genes therefore appears to be highly
specific.
In summary, the studies presented here strongly suggest
that targeting KDM4 with small-molecule inhibitors may provide
a therapeutic strategy for prostate cancer, especially CRPCs
that are refractory to anti-androgen therapies. Our discovery
that KDM4B can function as a BMYB co-activator also suggeststhat inhibition of KDM4 may be an effective therapeutic strategy
for other cancers.SIGNIFICANCE
The progression of prostate cancer from an androgen-
dependent to an androgen-independent/castration-resis-
tant state marks its lethal progression. Histone demethylase
KDM4s are known co-activators of the AR and are believed
to promote CRPCs through an AR-dependent mechanism.
Here, we identified a set of novel KDM4 inhibitors that
inhibited the growth of a variety of prostate cancer cell lines
including AR-negative PC3 cells and PC3 xenografts in vivo.
Using these inhibitors, we uncovered a novel AR-indepen-
dentmechanismbywhichKDM4Bpromotesprostate tumor-
igenesis. KDM4B activates the transcription of BMYB-tar-
geted genes such as PLK1 that are critical for cell-cycle
progression, and may be one of the mechanisms underlying
castration resistance. Our studies suggest that targetingChemistry & Biology 22, 1185–119KDM4B may provide an effective therapeutic strategy
for prostate cancers that are refractive to anti-androgen
therapies.
EXPERIMENTAL PROCEDURES
General Chemistry
Preparative purification was run on a Waters semi-preparative high-perfor-
mance liquid chromatography (HPLC) system using a Phenomenex Luna
C18 (5 mm, 30 3 75 mm) at a flow rate of 45 ml/min. A gradient of 10%–50%
acetonitrile in water over 8 min (each containing 0.1% trifluoroacetic acid
[TFA]) was used as a mobile phase during the purification. Fraction collection
was triggered by UV detection (220 nm). Analytical analysis was performed on
an Agilent LC/MS apparatus (Agilent Technologies). Method t1: A 7-min
gradient of 4%–100% acetonitrile (containing 0.025% TFA) in water (contain-
ing 0.05% TFA) was used with an 8-min run time at a flow rate of 1 ml/min. A
Phenomenex Luna C18 column (3 mm, 33 75 mm) was used at a temperature
of 50C. Method t2: A 3-min gradient of 4%–100% acetonitrile (containing
0.025% TFA) in water (containing 0.05% TFA) was used with a 4.5-min
run time at a flow rate of 1 ml/min. A Phenomenex Gemini Phenyl column
(3 mm, 33 100mm) was used at a temperature of 50C. Purity was determined
using an Agilent Diode Array Detector for both methods. Mass determination
was performed using an Agilent 6130 mass spectrometer with electrospray
ionization (ESI) in the positive mode. 1H NMR spectra were recorded on Varian
400-MHz spectrometer. Chemical shifts are reported in ppm with undeuter-
ated DMSO-d6 at 2.49 ppm as internal standard. High-resolution mass
spectrometry was recorded on Agilent 6210 Time-of-Flight liquid chromatog-
raphy-mass spectrometry (LC-MS) system. Confirmation of molecular formula
was accomplished using electrospray ionization in the positive mode with
Agilent Masshunter software (version B.02).
General Procedures
The detailed Experimental Procedures for the intermediates were described
previously (Rai et al., 2010–2012).Amixture of 3-(8-(2-(trimethylsilyl)ethoxy)quinolin-6-yl)benzoic acid (0.075 g,
0.205 mmol, 1 eq), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.079 g,
0.410 mmol, 2 eq), and 4-dimethylaminopyridine (0.013 g, 0.103 mmol,
0.5 eq) in N,N-dimethylformamine (0.5 ml) was added the amine (0.308 mmol,
1.5 eq) and stirred at room temperature for 2 hr. The reaction mixture was
filtered through a syringe filter and purified on a preparative HPLC. The product
obtained after lyophilization of the fractions was dissolved in dichloromethane/
TFA (2 ml, 1/2 by volume) and heated in a microwave for 15 min at 100C. The
crudeproduct obtained after removing the solventwaspurifiedonapreparative
HPLC to obtain the products as TFA salts.
3-(8-Hydroxyquinolin-6-yl)-N-(3-phenylpropyl)benzamide. TFA: LC-MS
retention time: t1 = 4.401 min and t2 = 2.717 min; 1H NMR (400 MHz,
DMSO-d6) d 10.59 (brs, 1H), 8.92 (dd, J = 4.5, 1.6 Hz, 1H), 8.70–8.57
(m, 2H), 8.24 (d, J = 1.9 Hz, 1H), 7.98–7.85 (m, 3H), 7.73 (dd, J = 8.5, 4.4 Hz,6, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1193
1H), 7.66–7.54 (m, 2H), 7.34–7.21 (m, 4H), 7.23–7.13 (m, 1H), 3.38–3.28
(m, 2H), 2.66 (t, J = 7.7 Hz, 2H), 1.93–1.81 (m, 2H); high-resolution mass spec-
trometry (HRMS) (ESI) m/z (M + H)+ calcd. for C25H23N2O2, 383.1754; found
383.1762.
N-(6-(Dimethylamino)hexyl)-3-(8-hydroxyquinolin-6-yl)benzamide. TFA: LC-
MS retention time: t1 = 3.162 min and t2 = 2.529 min; 1H NMR (400 MHz,
DMSO-d6) d 10.34 (s, 1H), 9.36 (s, 1H), 8.90 (dq, J = 5.3, 2.8, 2.3 Hz, 1H),
8.64 (d, J = 5.4 Hz, 1H), 8.52 (dt, J = 10.1, 2.9 Hz, 1H), 8.24 (p, J = 2.0 Hz,
1H), 7.98–7.79 (m, 3H), 7.77–7.50 (m, 4H), 3.31 (dd, J = 8.1, 4.5 Hz, 2H),
3.02 (dt, J = 9.2, 4.3 Hz, 2H), 2.79–2.71 (m, 6H), 1.61 (dd, J = 15.5, 9.0 Hz,
4H), 1.40–1.31 (m, 4H); HRMS (ESI) m/z (M + H)+ calcd. for C24H30N3O2,
392.2333; found 392.2325.Synthesis of 8-hydroxy-3-(4-(2-(naphthalen-1-yl)ethyl)-1,4-diazepan-1-yl)
quinoline-5-carboxylic acid. TFA: A mixture of methyl 3-iodo-8-(2-(trimethyl-
silyl)ethoxy)quinoline-5-carboxylate (0.2 g, 0.466 mmol, 1 eq), 1-(2-(naphtha-
len-1-yl)ethyl)-1,4-diazepane, 2HCl (0.229 g, 0.699 mmol, 1.5 eq), xantphos
(0.013 g, 0.023 mmol, 5 mol %), Pd2(dba)3 (10.66 mg, 0.012 mmol, 2.5 mol %)
and t-BuONa (0.157 g, 1.630 mmol, 3.5 eq) in toluene (3 ml) was bubbled with
argon for 5 min. The vial was sealed and stirred at 110C in a preheated heating
block for 4 hr. After completion of the reaction, the solvent was removed by
forced air. The crude mixture was taken up in DMSO and stirred with palladium
scavenger for 30 min. The solution was then filtered through a syringe filter and
purified on a preparative HPLC to obtain pure 3-(4-(2-(naphthalen-1-yl)ethyl)-
1,4-diazepan-1-yl)-8-(2-(trimethylsilyl)ethoxy)quinoline-5-carboxylic acid (0.1 g,
0.185 mmol). The above product was dissolved in dichloromethane/TFA (3 ml,
2/1 by volume) and stirred at 75C in a sealed tube for 1 hr. The crude product
was taken up in DMSO (2 ml) and purified on a preparative HPLC to obtain the
product as TFA salt. Retention time: t1 = 3.781 min and t2 = 2.726 min; 1H
NMR (400 MHz, DMSO-d6) d 12.48 (brs, 1H), 9.83 (brs, 1H), 8.71 (dt, J = 31.1,
2.8 Hz, 2H), 8.35–8.06 (m, 2H), 7.92 (ddd, J = 38.6, 7.7, 2.0 Hz, 2H), 7.73–7.34
(m, 4H), 6.82 (dd, J = 8.1, 2.5 Hz, 1H), 4.23–3.55 (m, 4H), 3.44–3.25 (m, 6H),
2.40–2.23 (m, 4H); HRMS (ESI)m/z (M + H)+ calcd. for C27H28N3O3.
Cell Lines and Antibodies
Cell lines and antibodies used are described in detail in Supplemental Exper-
imental Procedures.
Plasmids, Site-Directed Mutagenesis, Lentiviruses, Transfection,
and Luciferase-Reporter Assays
KDM4A plasmids were described previously (Zhang et al., 2011). KDM4B was
obtained fromAddgene. PLK1-luc was constructed by subcloning PCR-ampli-
fied humanPLK1 promoter fragments (Bra¨uninger et al., 1995) into pGL2-basic
(Promega) using KpnI and XhoI sites. Site-specific mutations were made
using a Quick-Change kit (Stratagene). Mutations were confirmed by DNA
sequencing. siRNA duplexes were purchased from Sigma and sequences
were listed in Table S1. Plasmids and siRNA transfection was performed using
lipofectamine 2000 and RNAimax, respectively. Transfections with LNCaP
cells were done using EZPlex (Ascension Bio). Luciferase activities were
measured with total cell lysates after 48 hr of transfection using a luciferase
assay kit (Promega). Relative promoter activities were expressed as relative
luminescence units normalized for co-transfected b-galactosidase activities
in the cell.1194 Chemistry & Biology 22, 1185–1196, September 17, 2015 ª201Cell Proliferation Assay
An MTT cell proliferation assay kit (ATCC) and trypan blue staining of live cells
were used to measure viable cells.
KDM4 Demethylase Activities
KDM4 demethylase activities were measured using an Epigenase JMJD2/
KDM4 demethylase assay kit (Epigentek, P-3081). Human KDM4B(1–500) pu-
rified from SF9 cells was purchased from BPS Bioscience. KDM4A(1–350),
KDM4C(1–350), and KDM4D(1–350) were purified as recombinant proteins
from Escherichia coli. These proteins were used to obtain the dose-response
curves of KDM4B enzymatic activity upon exposure to different concentra-
tions of KDM4 inhibitors. For measurement of total KDM4 activity in cells,
LNCaP cells were synchronized with the double thymidine block and har-
vested after they were released for indicated time points. Nuclear proteins
were isolated using standard protocol (Abcam) and quantified using Bradford
assays. A total of 10 mg of nuclear extracts were used to measure the KDM4
demethylase activity.
RNA and cDNA Preparation, Real-Time qRT-PCR, and Microarray
Analysis
Total RNA was isolated using an RNeasy Mini Kit (Qiagen). First-strand
cDNA was made using Superscript III Reverse Transcriptase (Invitrogen).
SYBR-based qRT-PCR was used to examine relative levels of selectedmRNAs. All data were normalized to an internal standard (GAPDH; DCT
method). Sequences for gene-specific primer pairs are listed in Table S1.
Microarray analyses were performed using an Illumina bead array platform.
Cell Synchronization, BrdU Labeling, and FACS
Cells were synchronized at the G1/S boundary by double thymidine treat-
ment. In brief, cells were incubated for 19 hr in 2 mM thymidine (Sigma),
released for 9 hr and then incubated for another 16 hr in 2 mM thymidine.
For BrdU labeling, asynchronous cells in culture were incubated with 20 mM
BrdU for 20 min before harvested for FACS analysis. Flow cytometry was car-
ried out using a FACSCalibur (BD Biosciences) and data were analyzed using
Flowjo software.
ChIP-qPCR
ChIP was carried out using the antibodies indicated in the figures and a proto-
col described previously (Zhang et al., 2011). Immunoprecipitated chromatin
fragments were quantified by SYBR-based qPCR, normalized using the
percent input method (Invitrogen). qPCR primers are listed in Table S1.
Western Blot, Immunoprecipitation, Protein Proximity Ligation
Assay, Immunofluorescence, and Immunohistochemistry
Western blot and immunoprecipitation were performed following standard
protocols. Immunohistochemical staining of AR and H3K9me3 on paraffin-
embedded human prostate tumors was performed following a previously
described procedure (Wei et al., 2010).
In Vivo TumorModel, Ex VivoCulture of HumanProstate Tumors, and
Drug Administration
For the xenograft animal model, PC3 cell suspension was injected into severe
combined immunodeficient (SCID) mice (4–6 weeks old) subcutaneously at
the concentration of 13 106 per site. When tumors become palpable, animals
were randomly grouped for drug treatment. An Alzet osmotic minipump
containing B3 (20 mg/kg) was subcutaneously inserted into each animal,
which allowed continuous drug delivery to the tumor site for up to 5 days.
Tumor volume was recorded every other day and calculated by using the
ellipsoid formula. All experimental procedures were approved by the Institu-
tional Animal Care and Use Committee. For ex vivo culture, fresh prostate
cancer tissues were obtained with informed consent from men undergoing
radical prostatectomy at the hospitals of the UT Southwestern (see Table S2
for clinicopathological characteristics). The procedure for establishment of
explant followed the previous description (Ravindranathan et al., 2013). Tis-
sues were cultured at 37C with vehicle (DMSO) alone or B3 (2.5 mM) for5 Elsevier Ltd All rights reserved
48 hr, then formalin-fixed and paraffin-embedded for immunohistochemistry
analyses or preserved in RNAlater (Invitrogen).
NMR
All NMR spectra were acquired at 25C on a Varian INOVA 600-MHz
spectrometer. Samples for 1H-15N TROSY-HSQC measurements contained
65 mM protein and 100 mM compounds B3 and A1 dissolved in 25 mM Tris (pH
7.4), 125mMNaCl, and 1mM tris(2-carboxyethyl)phosphinewith 5%D2O. Total
acquisition timeswere 2–10 hr. NMRdatawere processedwithNMRPipe (Dela-
glio et al., 1995) and analyzed with NMRView (Johnson and Blevins, 1994).
Statistics
All data are shown as mean ± SD or mean ± SEM as indicated in the figures.
Student’s t test (two-tailed) was used to compare the difference between
two groups. p < 0.05 was considered statistically significant. Gaphpad was
used to calculate IC50.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.08.007.
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